CLK1 and cancer: In this regard, targeting CLKs by RECTAS, with a target selectivity sufficient for a favorable safety profile in preclinical tests, may provide an alternative therapeutic strategy to target cancer cells with vulnerable splicing machinery or CLK-dependent causal splicing misregulation.